Sands Capital Alternatives, LLC — 13F Holdings & Portfolio
CIK 1846444 · latest 13F-HR filed 2026-05-08
Sands Capital Alternatives, LLC manages $421.2M in 13F-reported U.S. long-equity assets across 21 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are NU (22.30%), KVYO (16.86%), SGP (15.38%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 4, and trimmed 16.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$421.2M
Long-equity book
21
Distinct positions
2026-03-31
Filed 2026-05-08
+1 / −0 / ↑4 / ↓16
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- BIOAGE LABS INC$3.3M +32.2%
- 10X GENOMICS INC$2.4M +30.2%
- ACUMEN PHARMACEUTICALS INC$1.6M +21.8%
- SAMSARA INC$1.2M +7.4%
Top Trims
- BETA BIONICS INC-$71.6M -65.8%
- KLAVIYO INC-$47.5M -40.1%
- NU HLDGS LTD-$20.9M -18.2%
- MONDAY COM LTD-$5.3M -53.2%
- DOORDASH INC-$5.0M -22.9%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | NU HLDGS LTD | NU | G6683N103 | $93.9M | 22.30% | 6,537,769 | SH |
| 2 | KLAVIYO INC | KVYO | 49845K101 | $71.0M | 16.86% | 3,649,678 | SH |
| 3 | SPYGLASS PHARMA INC | SGP | 85220G109 | $64.8M | 15.38% | 2,500,012 | SH |
| 4 | BETA BIONICS INC | BBNX | 08659B102 | $37.2M | 8.82% | 3,708,043 | SH |
| 5 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $21.9M | 5.19% | 13,018,965 | SH |
| 6 | COUPANG INC | CPNG | 22266T109 | $19.1M | 4.54% | 1,012,091 | SH |
| 7 | SAMSARA INC | IOT | 79589L106 | $17.8M | 4.22% | 560,287 | SH |
| 8 | DOORDASH INC | DASH | 25809K105 | $16.7M | 3.97% | 111,231 | SH |
| 9 | BIOAGE LABS INC | BIOA | 09077V100 | $13.8M | 3.27% | 786,353 | SH |
| 10 | 10X GENOMICS INC | TXG | 88025U109 | $10.2M | 2.43% | 481,770 | SH |
| 11 | DATADOG INC | DDOG | 23804L103 | $10.1M | 2.40% | 85,793 | SH |
| 12 | ACUMEN PHARMACEUTICALS INC | ABOS | 00509G209 | $8.8M | 2.08% | 3,720,105 | SH |
| 13 | TOAST INC | TOST | 888787108 | $8.0M | 1.90% | 301,647 | SH |
| 14 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $6.0M | 1.42% | 85,000 | SH |
| 15 | SERVICETITAN INC | TTAN | 81764X103 | $5.7M | 1.35% | 89,856 | SH |
| 16 | MONDAY COM LTD | MNDY | M7S64H106 | $4.7M | 1.11% | 67,868 | SH |
| 17 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $3.2M | 0.77% | 724,873 | SH |
| 18 | SNOWFLAKE INC | SNOW | 833445109 | $3.1M | 0.73% | 20,253 | SH |
| 19 | ACRIVON THERAPEUTICS INC | ACRV | 004890109 | $3.0M | 0.70% | 2,122,605 | SH |
| 20 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $2.0M | 0.47% | 405,837 | SH |
| 21 | FIGMA INC | FIG | 316841105 | $386.6K | 0.09% | 18,286 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | $421.2M | 21 | 0001846444-26-000005 |
| 2025-12-31 | 2026-02-13 | $518.5M | 20 | 0001846444-26-000003 |